NCT02084199View on ClinicalTrials.gov

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Renal Impairment

Interventions

DRUG

GLPG0634

100 mg oral tablet, intake once daily for 10 days

Trial Locations (1)

Unknown

CRS Clinical Research Services Kiel GmbH, Kiel

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galapagos NV

INDUSTRY